On April 14, 2026, a significant federal product liability lawsuit was filed in the Northern District of Texas, exposing the dangerous intersection of aesthetic medicine and regulatory non-compliance. In Thompson v. Feel Tech Co., Ltd., et al., four women are suing a global network of manufacturers and distributors after a routine “thread lift” procedure allegedly left them with treatment-resistant bacterial infections and permanent facial scarring.
As a personal injury attorney, this case represents a “perfect storm” of corporate misconduct: the marketing of a medical device for uses explicitly excluded by the FDA.
The Incident: A Cluster of Treatment-Resistant Infections
Between April 16 and April 23, 2024, the four Plaintiffs underwent procedures at a Dallas cosmetic facility using the Miracu PDO Mono Thread. Shortly thereafter, each developed a severe infection of Mycobacterium abscessus, a cluster of antibiotic-resistant bacteria. The resulting medical ordeal included:
- Surgical drainage of facial abscesses.
- PICC line placement for prolonged intravenous (IV) antibiotic therapy.
- Permanent facial disfigurement and scarring.
The Regulatory Breach: “Not Intended for Lifting”
The core of the legal argument is a staggering regulatory failure. The complaint alleges that while the Miracu Mono Thread eventually received an FDA 510(k) clearance, that clearance explicitly stated the product was “not intended for lifting and supporting tissues.” Despite this, the Defendants, ranging from the South Korean manufacturer Feel Tech to the California-based DBM Corporation USA, allegedly marketed the product through promotional materials, distributor communications, and sales calls to heath care practitioners, for the facial tissue enhancement and tightening procedures that caused the Plaintiffs’ injuries.
Calculating the Award: More Than Just Medical Bills
In a complex product liability case like this, an effective attorney must look far beyond the immediate surgical costs. The “award amount” is a calculation of both objective and subjective losses:
- Economic Damages: These are the hard numbers, including the cost of the PICC line installations, the high-priced specialized IV antibiotics, and lost wages or loss of earning capacity for women who may be unable to work during months of treatment.
- Non-Economic Damages: This is the most significant portion of the claim. In Texas, “disfigurement” is a separate category of damages. An attorney must quantify the mental anguish and “physical impairment” of a young woman living with permanent facial scars caused by a procedure that was supposed to enhance her appearance.
- Exemplary Damages: Because the Plaintiffs allege the Defendants acted with “knowing disregard” for the product’s regulatory status, they are seeking damages meant to punish the companies. This is calculated based on the net worth of the defendants and the degree of their “conscious indifference” to patient safety.
What an Effective Attorney Does
This filing demonstrates the high-level strategy required to hold international corporations accountable:
- Establishing “Single Enterprise” Liability: The attorneys in this case didn’t just sue the local distributor; they pierced the corporate veil by showing that DBM and BENEV share the same address, officers, and directors, operating as a “single enterprise.”
- Utilizing Federal Rule 4(k)(2): To bring the South Korean manufacturer Feel Tech into a Texas court, the attorneys invoked Rule 4(k)(2), arguing that Feel Tech’s extensive U.S. regulatory filings and distribution network satisfy the “minimum contacts” required for federal jurisdiction.
- The FDA Deep Dive: An effective attorney acts as a forensic regulator. By digging into the specific 510(k) clearance numbers (K172602 and K251414), they were able to prove that the manufacturer was expressly told not to use the product for lifting—information that will be devastating in front of a jury.
As this case moves forward in the Northern District of Texas, it serves as a warning to the aesthetic industry: off-label marketing is not just a regulatory risk; it is a multi-million dollar liability waiting to happen.
